Mode
Text Size
Log in / Sign up
N/A N=93 Randomized Treatment

Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID

Long COVID · Pain

Enrolled (actual)
93
Serious AEs
22.6%
Results posted
May 2026
Primary outcome: Primary: Pain, Enjoyment and General Activity (PEG) — 6.74; 6.74; 8.33; 9.33 Score

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Acupuncture (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Washington
Primary completion
Mar 2025

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain, Enjoyment and General Activity (PEG)
6.74; 6.74; 8.33; 9.33; 4.95; 6.03
SECONDARY
Pain Catastrophizing Scale (PCS) Short Form
12.37; 12.62; 9.48; 11.68; 7.52; 11.97
SECONDARY
PROMIS-29
37.44; 37.62; 38.95; 37.03; 40.39; 37.97
SECONDARY
PROMIS Cognitive Function
33.52; 31.56; 35.62; 33.04; 37.87; 32.92
SECONDARY
UW Pain Related Self-Efficacy Scale (PRSE)
44.24; 43.71; 47.75; 45.23; 44.9; 44.98

Summary

The goal of this preliminary study is to test methods and procedures to be used in a fully-powered trial to evaluate acupuncture treatment effectiveness. Specifically, we will test the feasibility of conducting a 2-arm randomized clinical trial for evaluating the effectiveness of acupuncture for pain in patients with long COVID. Researchers will compare pain intensity and impact on general activities over 5 months in those who receive acupuncture treatment compared to patients who are receiving usual long COVID care. Participants will complete 4 online surveys at weeks 0, 4, 8, and 20. These surveys include validated mental and physical health questionnaires. Participants who are randomly selected to receive the intervention will receive 8 acupuncture treatment sessions.

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age at the time of consent.
  • Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization
  • Report pain symptoms including musculoskeletal pain (joint, muscle, bone pain), chest pain, abdominal pain, headache, back pain, nerve pain, and pain in ear following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent.
  • Report pain intensity (0-10 scale) ≥4 in the last 7 days.28
  • As of today, has been seen by a clinician in the UW Long COVID Clinic either in-person or via telehealth/virtual visit
  • Able to speak and read English and provide informed consent to complete the study requirements.

Exclusion Criteria

  • <18 years of age at the time of consent.
  • Reports absence of pain, pain for less than 12 weeks, or a pain intensity <4 over the last 7 days.
  • Report baseline level of pain for those who have pre-existing chronic pain (i.e., chronic pain condition(s) present prior to COVID-19 illness AND chronic pain not worsened post-COVID).
  • Already received acupuncture treatment for long COVID symptoms.
  • Unable to travel to the UW Northgate Clinic once a week for 8 weeks for acupuncture treatments.
  • Has seizure disorder with high risk of seizure (i.e., new diagnosis of seizure disorder and/or new medication in the last 3 months, or uncontrolled/unclear triggers for seizures).
  • Is currently Pregnant
  • Is receiving active cancer therapy
  • Has severe neutropenia (<500 WBC) due to any cause within the last 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06476496). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search